查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595214

阵发性夜间血尿症治疗市场：透过诊断测试、治疗 - 全球预测 2025-2030

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Diagnostic Test (Bone Marrow Examination, Complete Blood Count Test, Flow Cytometry), Treatment (Blood Transfusion, Medication, Stem Cell Transplant) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

阵发性夜间血尿症治疗市场2023年估值为31.5亿美元，预计2024年将达34.9亿美元，复合年增长率为10.88%，2030年将达65亿美元，预计将达到1000万美元。

阵发性夜间血尿症(PNH) 是一种罕见的危及生命的疾病，其特征是红血球破坏、血栓和骨髓功能受损。 PNH 的治疗包括依Eculizumab)和拉维珠单抗 (Ravulizumab)等药物，这些药物以补体抑制为目标，以减少溶血并控制症状。需求在于与 PNH 相关的严重併发症，强调需要有效的治疗来提高患者的生活品质和存活率。应用范围从血液学到个人化护理非常重要的专业医疗机构。最终用途包括医院、临床研究机构、专科诊所等。市场成长在很大程度上受到意识提高、生物医学研究进步以及新治疗方法的可用性的影响。政府对孤儿药的支持以及生技公司之间的合作正在帮助扩大市场。需求未满足的地区存在商机，特别是在医疗基础设施欠发达的地区，这表明市场存在地理和人口扩张的可能性。透过数位医疗平台增强病人参与带来了进一步的成长机会。然而，它面临着高昂的治疗成本和有限的患者数量以及医药品认证过程中的监管障碍的挑战。此外，对疾病机制的了解有限也限制了创新。然而，市场上的一些研究领域有望简化治疗通讯协定，例如基因治疗和更有效的诊断工具。对临床试验和研究合作的持续投资可以带来突破性创新。市场的利基但不断发展的性质要求相关人员在引入新技术时保持敏捷。投资意识宣传活动和利用患者的倡导也可以推动参与。透过解决这些动态，公司可以克服 PNH 治疗市场固有的复杂性，同时利用扩张机会。

主要市场统计
基准年[2023] 31.5亿美元
预测年份 [2024] 34.9亿美元
预测年份 [2030] 65.1亿美元
复合年增长率（%） 10.88%

市场动态：快速阵发性夜间血尿症治疗市场的关键市场洞察

供给和需求的动态交互作用正在改变阵发性夜间血尿症治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 新疗法的采用增加
    • 人口老化的加剧和生技药品的兴起
    • 血液和骨髓相关疾病增加
  • 市场限制因素
    • 治疗高成本
  • 市场机会
    • 增加干细胞研究和开发
    • 加大PNH治疗研发投入
  • 市场挑战
    • 现有治疗方法的副作用

波特五力：驾驭阵发性夜间血尿症治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解阵发性夜间血尿症治疗市场的外部影响

外部宏观环境因素在塑造阵发性夜间血尿症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解阵发性夜间血尿症治疗市场的竞争格局

对阵发性夜间血尿症治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵阵发性阵发性夜间血尿症治疗市场供应商的绩效评估

FPNV定位矩阵是评估阵发性夜间血尿症治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了阵发性夜间血尿症治疗市场的成功之路

对阵发性夜间血尿症治疗市场的策略分析对于希望加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 增加新治疗方法的采用
      • 人口老化的加剧和生物製药的出现
      • 血液和骨髓相关疾病增加
    • 抑制因素
      • 医疗费用上涨
    • 机会
      • 干细胞研究进展
      • 加大PNH治疗研发投入
    • 任务
      • 现有治疗方法的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章阵发性夜间血尿症治疗市场诊断测试

  • 骨髓检查
  • 全血球计数测试
  • 流式细胞技术
  • 乳酸脱氢酵素测试
  • 含铁血黄素尿液检查

第七章阵发性夜间血尿症治疗市场（依治疗）

  • 输血
  • 药物治疗
  • 干细胞移植

第八章北美与南美阵发性夜间血尿症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区阵发性夜间血尿症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲阵发性夜间血尿症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Akari Therapeutics, PLC
  • Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amyndas Pharmaceuticals
  • Apellis Pharmaceuticals, Inc.
  • CinnaGen Co.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Ra Pharma by Cohance Lifesciences
  • Regeneron Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-036C5CF3B54F

The Paroxysmal Nocturnal Hemoglobinuria Treatment Market was valued at USD 3.15 billion in 2023, expected to reach USD 3.49 billion in 2024, and is projected to grow at a CAGR of 10.88%, to USD 6.51 billion by 2030.

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, life-threatening disease characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. The scope of PNH treatment involves medications like eculizumab and ravulizumab targeting complement inhibition to reduce hemolysis and manage symptoms. The necessity lies in the severe complications associated with PNH, underscoring the need for effective treatments to improve patients' quality of life and survival rates. Application extends to hematology and specialized healthcare facilities where personalized care is crucial. End-use scope prominently includes hospitals, clinical research institutes, and specialty clinics. Market growth is significantly influenced by increased awareness, advances in biomedical research, and the availability of novel therapies. Government support for orphan drugs and collaborations between biotech firms are aiding market expansion. Opportunities arise in unmet clinical needs, particularly in regions lacking robust healthcare infrastructure, hinting at potential geographic and demographic market expansion. Enhancing patient engagement through digital healthcare platforms presents additional opportunities for growth. However, high treatment costs and limited patient population pose challenges, alongside regulatory hurdles in drug approval processes. Furthermore, the limited understanding of the disease mechanism poses constraints on innovation. Nonetheless, the market presents areas ripe for research, such as genetic therapies and more efficient diagnostic tools, promising to ease treatment protocols. Continued investment in clinical trials and collaborative research could foster breakthrough innovations. The nature of the market is niche yet evolving, requiring stakeholders to maintain agility in adopting emerging technologies. Investment in awareness campaigns and leveraging patient advocacy can also drive engagement. By addressing these dynamics, companies can harness expansion opportunities while navigating the complexities inherent in the PNH treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 3.15 billion
Estimated Year [2024] USD 3.49 billion
Forecast Year [2030] USD 6.51 billion
CAGR (%) 10.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The Paroxysmal Nocturnal Hemoglobinuria Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of novel therapeutics
    • Rising geriatric population and the emergence of biologics
    • Growing number of blood and bone marrow related disorders
  • Market Restraints
    • High costs associated with medical treatment
  • Market Opportunities
    • Increasing development in stem cell research
    • Rising investment in research & development of PNH treatment drugs
  • Market Challenges
    • Adverse side effects with existing treatments

Porter's Five Forces: A Strategic Tool for Navigating the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

A detailed market share analysis in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Paroxysmal Nocturnal Hemoglobinuria Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market

A strategic analysis of the Paroxysmal Nocturnal Hemoglobinuria Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics, PLC, Alexion Pharmaceuticals, Inc. by AstraZeneca PLC, Alnylam Pharmaceuticals, Inc., Amgen Inc., Amyndas Pharmaceuticals, Apellis Pharmaceuticals, Inc., CinnaGen Co., F. Hoffmann-La Roche AG, Novartis AG, Ra Pharma by Cohance Lifesciences, Regeneron Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Paroxysmal Nocturnal Hemoglobinuria Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnostic Test, market is studied across Bone Marrow Examination, Complete Blood Count Test, Flow Cytometry, Lactate Dehydrogenase Test, and Urine Test for Hemosiderin.
  • Based on Treatment, market is studied across Blood Transfusion, Medication, and Stem Cell Transplant.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of novel therapeutics
      • 5.1.1.2. Rising geriatric population and the emergence of biologics
      • 5.1.1.3. Growing number of blood and bone marrow related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with medical treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing development in stem cell research
      • 5.1.3.2. Rising investment in research & development of PNH treatment drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse side effects with existing treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Diagnostic Test

  • 6.1. Introduction
  • 6.2. Bone Marrow Examination
  • 6.3. Complete Blood Count Test
  • 6.4. Flow Cytometry
  • 6.5. Lactate Dehydrogenase Test
  • 6.6. Urine Test for Hemosiderin

7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Blood Transfusion
  • 7.3. Medication
  • 7.4. Stem Cell Transplant

8. Americas Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akari Therapeutics, PLC
  • 2. Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
  • 3. Alnylam Pharmaceuticals, Inc.
  • 4. Amgen Inc.
  • 5. Amyndas Pharmaceuticals
  • 6. Apellis Pharmaceuticals, Inc.
  • 7. CinnaGen Co.
  • 8. F. Hoffmann-La Roche AG
  • 9. Novartis AG
  • 10. Ra Pharma by Cohance Lifesciences
  • 11. Regeneron Pharmaceuticals, Inc.
  • 12. Samsung Bioepis Co., Ltd.
  • 13. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BONE MARROW EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLETE BLOOD COUNT TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LACTATE DEHYDROGENASE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY URINE TEST FOR HEMOSIDERIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023